Cryolife (CRY) Gets a Buy Rating from Needham
In a report released today, Michael Matson from Needham assigned a Buy rating to Cryolife (CRY), with a price target of $33.00. The company’s shares closed last Wednesday at $22.67.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 17.1% and a 72.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cryolife with a $31.00 average price target.
See today’s analyst top recommended stocks >>
Cryolife’s market cap is currently $891.2M and has a P/E ratio of -50.00. The company has a Price to Book ratio of -5.55.
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.